Navigation Links
BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
Date:4/8/2008

ut Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' collaboration with Bristol-Myers Squibb, and the discovery and development of drugs for prevention and treatment of cardiovascular disease and high cholesterol including the newly selected development candidate. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trad
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
6. EDS Awarded $715 Million Contract for Bristol-Myers Squibb Information Services
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31
9. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
10. Bristol-Myers Squibb Announces Dividend
11. Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... believe is the thinnest-possible semiconductor, a new class ... atoms thick. , The University of Washington researchers ... materials can be connected in an atomically seamless ... be the basis for next-generation flexible and transparent ... technologies. , "Heterojunctions are fundamental elements of electronic ...
(Date:8/26/2014)... The 20 ambassadors representing the ALS ... issued the following statement on Facebook today regarding the ... new funding specifically for ALS research: , “Who would ... ice would raise all this awareness and funding toward ... on behalf of the entire ALS community, would like ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... strains in Pubmed, has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
(Date:8/26/2014)... San Francisco, CA (PRWEB) August 26, 2014 ... to reach USD 8,020.1 million by 2020, according to ... demand for personalized medicine and theranostics, and the subsequent ... be key factors driving market growth over the next ... population and chronic diseases such as cancer, coupled with ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6
... FREMONT, Calif., Dec. 14 Vermillion, Inc. (Pink Sheets: ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice President, Research ... board of directors upon confirmation of Vermillion,s bankruptcy plan. ... and development experience in diagnostics and biotechnology," said Gail ...
... , , , NATICK, Mass., Dec. ... announced the completion of a public offering of $2 billion aggregate ... statement. The public offering consists of $850 million of 4.50 ... due January 2020 and $300 million of 7.375 percent notes due ...
... ... the delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move from sheet ... , ... December 14, 2009 -- ThermoFab, a US-based thermoforming company, has completed the delivery of ...
Cached Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
(Date:8/26/2014)... of harmful bacteria, biofilms make the treatment of ... biofilm pose a significant health risk due to ... biofilm-protected bacteria account for some 80 percent of ... to 1,000 times more resistant to antibiotics than ... have stumbled onto a magic bullet," said David ...
(Date:8/26/2014)... succeeded in obtaining an unprecedented view of a ... a range of neurological illnesses, including Alzheimer,s disease, ... associated with stroke. , The team of biologists ... Department of Energy,s Advanced Photon Source at Argonne ... the intact NMDA (N-methyl, D-aspartate) receptor should serve ...
(Date:8/26/2014)... endemic tree has for the last 31 years been incorrectly ... and small trees. A New Zealand botanist has completed a ... diversity behind what was long considered a single tree species. ... PhytoKeys . , Known to botanists as ... discoveries made in the north-western South Island of New Zealand ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3
... life in higher animals, vitamin D, once linked to only ... as a major player in contributing to overall human health, ... on vitamin D. In a paper published in the ... Nutrition , Norman identifies vitamin D,s potential for contributions ...
... Carolina State University is leading to a new kind ... from freshwater ponds, instead of from the sea. ... crabs look and taste just like their ocean-raised brethren. ... at historic lows since 2000. Dr. Dave Eggleston, director ...
... develop sustainable energy systems while reducing the harmful ... phased out over the next century. This optimistic ... technologies such as biomimetics and Dye Sensitized solar ... or storing solar energy, and nanocatalysis develops efficient ...
Cached Biology News:Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 3Turning freshwater farm ponds into crab farms 2Europe rallies behind nanotechnology to wean world from fossil fuels 2Europe rallies behind nanotechnology to wean world from fossil fuels 3Europe rallies behind nanotechnology to wean world from fossil fuels 4
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Biology Products: